Lhuissier, E.; Aury-Landas, J.; Lenté, M.; Boumediene, K.; Baugé, C.
Co-Treatment with the Epigenetic Drug, 3-Deazaneplanocin A (DZNep) and Cisplatin after DZNep Priming Enhances the Response to Platinum-Based Therapy in Chondrosarcomas. Cancers 2021, 13, 4648.
https://doi.org/10.3390/cancers13184648
AMA Style
Lhuissier E, Aury-Landas J, Lenté M, Boumediene K, Baugé C.
Co-Treatment with the Epigenetic Drug, 3-Deazaneplanocin A (DZNep) and Cisplatin after DZNep Priming Enhances the Response to Platinum-Based Therapy in Chondrosarcomas. Cancers. 2021; 13(18):4648.
https://doi.org/10.3390/cancers13184648
Chicago/Turabian Style
Lhuissier, Eva, Juliette Aury-Landas, Marion Lenté, Karim Boumediene, and Catherine Baugé.
2021. "Co-Treatment with the Epigenetic Drug, 3-Deazaneplanocin A (DZNep) and Cisplatin after DZNep Priming Enhances the Response to Platinum-Based Therapy in Chondrosarcomas" Cancers 13, no. 18: 4648.
https://doi.org/10.3390/cancers13184648
APA Style
Lhuissier, E., Aury-Landas, J., Lenté, M., Boumediene, K., & Baugé, C.
(2021). Co-Treatment with the Epigenetic Drug, 3-Deazaneplanocin A (DZNep) and Cisplatin after DZNep Priming Enhances the Response to Platinum-Based Therapy in Chondrosarcomas. Cancers, 13(18), 4648.
https://doi.org/10.3390/cancers13184648